What Is the 340B Drug Discount Program?
The 340B Drug Pricing Program is a federal initiative. It requires pharmaceutical manufacturers to offer reduced drug prices to certain hospitals and health clinics. These facilities typically serve low-income and uninsured patients.
Hospitals that qualify for the program use the savings in several important ways. First, they reinvest funds into patient care services. Second, they expand access to medications for vulnerable populations. Third, they offset losses from treating Medicaid and uninsured patients.
The program covers thousands of hospitals across the United States. Today, more than 2,300 hospital systems actively participate. Consequently, any disruption to 340B pricing has a broad financial impact on the healthcare system.
Why the Program Matters for Safety-Net Hospitals
Safety-net hospitals depend heavily on 340B savings. Without these discounts, many facilities struggle to maintain services. Moreover, lower-income communities feel the loss most acutely. The 340B program, therefore, functions as a financial lifeline for these institutions.
Why Did Eli Lilly Cut the Discounts?
In June 2026, Eli Lilly stopped providing 340B discounts to certain hospitals. The company cited a specific reason: it wanted to eliminate what it calls “duplicate discounts.”
The Claims Data Dispute
Earlier this year, Lilly introduced a new policy. Under this policy, participating hospitals must submit claims data to the company. Lilly argues the data helps it verify that discounts are applied correctly and not duplicated.
However, many hospitals refused to comply. They objected to sharing detailed patient claims information with a pharmaceutical manufacturer. As a result, Lilly suspended discounts for non-compliant facilities.
How Many Hospitals Did Lilly Target?
Lilly did not cut discounts across the board. Instead, it focused on 50 larger hospital systems. These systems were selected from roughly 1,000 hospitals that had not met the new data-sharing requirement.
By contrast, approximately 70% of 340B-eligible hospitals—more than 2,300 facilities—had already submitted claims data. Therefore, most participating hospitals kept their discount access intact.
How Lawmakers Are Responding
Dozens of congressional lawmakers have now stepped into the dispute. They sent a formal letter to Department of Health and Human Services Secretary Robert F. Kennedy Jr. Their message was direct: force Lilly to reinstate the discounts immediately.
A Bipartisan Call to Action
Notably, the lawmakers represent both political parties. This bipartisan response signals broad concern about Lilly’s move. The letter argues that Lilly violates federal law by withholding the required price breaks.
Furthermore, the lawmakers expressed concern about the financial impact on hospitals. Losing 340B discounts creates immediate budget pressure. For many hospital systems, those savings fund critical programs that would otherwise disappear.
The Legal Argument Against Lilly
The lawmakers’ letter rests on a clear legal argument. Federal law mandates that drug manufacturers provide 340B discounts to eligible hospitals. According to the bipartisan group, Lilly cannot impose unilateral conditions—such as claims data requirements—to bypass that obligation.
However, Lilly maintains its position. The company insists that its claims data policy is a legitimate tool to prevent duplicate discounting. Thus, the dispute now hinges on how HHS interprets the law.
Which Hospitals Are Affected?
The hospitals facing discount loss are largely larger systems. Lilly targeted 50 systems specifically because of their size and data non-compliance. Smaller hospitals that had already submitted data continued to receive their discounts without interruption.
Financial Stakes for Health Systems
The financial consequences are significant. Large hospital systems use 340B savings to fund pharmacy programs, outpatient clinics, and specialty care units. Losing those discounts forces administrators to make difficult budget choices.
Additionally, some hospitals serve regions with few other healthcare options. In those communities, funding cuts translate directly into reduced services. Consequently, patients—not just hospitals—bear the real cost of this dispute.
What Comes Next for 340B Policy?
The outcome depends largely on how HHS responds to congressional pressure. Secretary Kennedy Jr. now faces a high-profile decision. He must decide whether to enforce existing 340B rules against Lilly or allow the company’s claims data policy to stand.
Potential HHS Enforcement Action
If HHS sides with lawmakers, it could order Lilly to restore discounts immediately. Furthermore, regulators could penalize Lilly for non-compliance with the 340B statute. That outcome would set a strong precedent for manufacturer conduct across the entire program.
Industry-Wide Implications
This dispute extends well beyond Eli Lilly. Other pharmaceutical manufacturers are watching closely. If Lilly succeeds in conditioning discounts on claims data, other companies may follow with similar requirements.
Hospitals and advocacy groups worry about that precedent. They argue it would fundamentally undermine the 340B program’s mission. Therefore, the stakes of this policy battle reach far beyond a single drug company’s dispute with 50 hospital systems.
